ArticleBMC gastroenterology2025
Predictive role of the Albumin-Bilirubin score in ICU patients with cirrhosis and sepsis: insights from a large retrospective cohort.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Value of albumin-bilirubin (ALBI) Grade in Patients with Gastric Cancer: A Systematic Review and meta-analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Early Total Bilirubin Trajectories During the First 72 Hours After ICU Admission With Mechanical Ventilation and Short-Term Mortality: A Multicenter Cohort Study.Critical care explorations · 2026Article
- Association of the Albumin-Bilirubin score with 7-day incident delirium risk following bloodstream infection in critically ill adults: evidence from a propensity-weighted cohort.BMC infectious diseases · 2026Article
- Development and external validation of a predictive model for in-hospital mortality in patients with liver cirrhosis and sepsis.Scientific reports · 2026Article
- Mortality predictors, hepatic involvement patterns, and the steatotic liver paradox in 1,484 hospitalized Dengue patients.PloS one · 2026Article
- A cluster analysis of 466 patients demonstrates that glutathione supplementation could preferentially benefit advanced unstable cirrhosis phenotype rather than stable cirrhosis.Frontiers in pharmacology · 2026Article
- Albumin-bilirubin score as a practical tool for prognostication in metabolic-associated steatotic liver disease.World journal of hepatology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe albumin-bilirubin (ALBI) score is a valuable prognostic tool for diseases such as hepatocellular carcinoma, heart failure, and acute kidney injury. However, its association with the prognosis of patients with liver cirrhosis and sepsis in the intensive care unit (ICU) remains unclear.
methodsThis retrospective study analyzed data from ICU patients with liver cirrhosis and sepsis admitted to the Beth Israel Deaconess Medical Center between 2008 and 2022. The primary and secondary endpoints were 28-day (short-term) and 90-day (long-term) mortality, respectively. Relationships between mortality risk and the ALBI scores were assessed by Kaplan-Meier, multivariable Cox proportional hazard, and restricted cubic spline (RCS) analyses. The receiver operating characteristic (ROC) curves were used to evaluate the predictive ability of the ALBI score for 28-day and 90-day mortality in these patients. Subgroup analyses were used to explore the associations between the ALBI scores and different patient populations.
resultsThe study included 2,047 ICU patients with liver cirrhosis and sepsis. Patients with higher ALBI scores had significantly higher 28-day and 90-day mortality rates than those with lower scores (Kaplan-Meier). The ALBI score was an independent predictor of short-term and long-term mortality (multivariable Cox regression). In the fully adjusted model, the hazard ratios (HRs) for the ALBI score as a continuous variable were 1.38 (95% confidence interval [CI]: 1.20–1.58, P < 0.001) and 1.33 (95% CI: 1.18–1.50, P < 0.001) for 28-day and 90-day mortality, respectively. When categorized into tertiles, the mortality risk was significantly higher for patients in the highest tertile than for those in the lowest tertile, with HRs of 1.51 (95% CI: 1.23–1.85, P for trend < 0.001) and 1.45 (95% CI: 1.21–1.73, P for trend < 0.001) for 28-day and 90-day mortality, respectively. A nonlinear relationship was identified between the ALBI score and short- and long-term mortality (RCS analysis). The results of the ROC curve analysis confirmed that the predictive ability of the ALBI score for 28-day and 90-day mortality was not inferior to that of the Sequential Organ Failure Assessment score. Subgroup analyses showed that there were no significant interactions between ALBI scores and the vast majority of subgroups.
conclusionsHigher ALBI scores were significantly and independently associated with increased short- and long-term mortality in ICU patients with liver cirrhosis and sepsis. The ALBI score may help with risk and prognostic evaluations in this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.